Prodrugs of inhibitors of plasma kallikrein

1. A compound having the formula:

wherein

Ar is benzene, m is an integer from 0-5;

X is selected from the group consisting of H, C 1-8 alkyl and phenyl;

each R a is independently selected from the group consisting of halogen, —OR 1 and —R 1 ,

wherein each R 1 is independently alkyl;

L is a linking group selected from the group consisting of a bond and CH 2 ;

Q a and Q C are each C(R q ) wherein each R q is independently selected from the group consisting of H, C 1-8 alkyl, and halogen;

Q b is N;

Y is N; and the ring having Q a , Q b , Q c , and Y as ring vertices is a five- membered ring having two double bonds;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein X is selected from the group consisting of H, methyl, ethyl and pentyl.

3. The compound of claim 1 wherein L is a bond.

4. The compound of 1 having the formula:

wherein Ar is a benzene ring and X is selected from the group consisting of H and C 1 -C 5 alkyl.

5. The compound of claim 4 , wherein each R q is independently selected from the group consisting of H, halogen and methyl.

6. The compound of claim 4 , wherein L is —CH 2 —.

7. The compound of claim 4 , wherein Ar is a benzene ring, m is 0, each R q is H, and L is a bond.

8. The compound of claim 4 , wherein Ar is a benzene ring, m is 0, each R q is H, and L is —CH 2 —.

9. The compound of claim 1 , selected from the group consisting of:

(a) (Z)-hexyl amino-(4-((1-benzylpyrazole-4-carbonylamino)methyl)phenyl)methylenecarbamate

(b) (Z)-methyl amino-(4-((1-benzylpyrazole-4-carbonylamino)methyl) phenyl)methylenecarbamate

(c)(Z)-benzyl amino-(4-((1-benzylpyrazole-4-carbonylamino)methyl) phenyl)methylenecarbamate

(d)(Z)-ethyl amino-(4-((1-benzylpyrazole-4-carbonylamino)methyl) phenyl)methylenecarbamate, and

(e)(Z)-propyl amino-(4-((1-benzylpyrazole-4-carbonylamino)methyl)phenyl)methylenecarbamate.